Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has granted equity inducement awards to 11 new non-executive employees.

Under the company's 2025 Inducement Plan, the employees received a total of 6,940 time-based restricted stock units. These units will vest in four equal annual installments, subject to continued employment. The awards were approved by Madrigal's independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

+1.86%

4 alerts

+1.86% News Effect

+$168M Valuation Impact

$9.19B Market Cap

0.7x Rel. Volume

On the day this news was published, MDGL gained 1.86%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $168M to the company's valuation, bringing the market cap to $9.19B at that time.

Data tracked by StockTitan Argus on the day of publication.

CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2025 to 11 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 6,940 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal Pharmaceuticals (MDGL) grant to new employees in August 2025?

Madrigal granted 6,940 time-based restricted stock units to 11 new non-executive employees under its 2025 Inducement Plan.

How will the restricted stock units vest for Madrigal Pharmaceuticals' new employees?

The restricted stock units will vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.

When did Madrigal Pharmaceuticals (MDGL) grant these inducement awards?

The equity awards were granted on August 15, 2025 and announced on August 21, 2025.

What is the purpose of Madrigal Pharmaceuticals' inducement awards?

The equity awards were granted as inducement material to employees' acceptance of employment with the company, approved under Nasdaq Listing Rule 5635(c)(4).